All Cognitive Disorders/Dementia

The US Food and Drug Administration (FDA) announced on June 7, 2021, the approval of aducanumab (Aduhelm). The drug was approved under the Accelerated Approval pathway, one of the alternative drug approval pathways.

In addition to our latest articles on cognitive disorders and dementia, Neurology has included a list of aducanumab resources on this page to help our members stay informed on the current landscape of the new Alzheimer disease drug.

  Featured Editorials and Viewpoints

Clinical Efficacy, Drug Safety and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
Linda A. Hershey, Rawan Tarawneh 

...the patient and their caregivers need to understand that the clinical benefits of aducanumab are small and that more data will be needed in the future to determine whether these benefits are clinically or functionally meaningful to patients. [Read Article]

Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Stephen Salloway, Jeffrey Cummings

Aducanumab opens a new era in AD research and care and provides a foundation for development of progressively better therapies. [Read Article]

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
David S. Knopman, Joel S. Perlmutter 

On the one hand, neurologists want to offer hope. Yet, aducanumab’s benefits are meager, if even present and there are non-trivial risks of side effects. [Read Article]

  Aducanumab Podcasts

View All Episodes